Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

European Journal of Cancer and Clinical Oncology

Volumn 23, Issue 9, 1987, Pages 1409-1411

  Postmus, Pieter E ^a   Berendsen, Henk H ^a   van Zandwijk, Nico ^b   Splinter, Ted A W ^c   Burghouts, Jos Th M ^d   Bakker, Wim ^e  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d Groot Zieken Gasthuis Den Bosch The Netherlands ^*

^e Department of Pulmonary Diseases State Univeristy ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

CLINICAL ARTICLE; HUMAN; HUMAN EXPERIMENT; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; ETOPOSIDE; HUMAN; LUNG NEOPLASMS; MIDDLE AGE; RECURRENCE; REMISSION INDUCTION;

EID: 0023519996     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(87)90128-3     Document Type: Article

References (7)

1. Etoposide and cisplatin: an active treatment for relapse in small cell lung cancer
2. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates
3. A randomised trial in 516 patients with small cell lung cancer comparing (1) two durations of initial chemotherapy (I.Ct.) and (2) further therapy (Rel.Ct.) or symptomatic treatment alone (sympt) at the time of disease progression
4. Reinduction prolongs survival in complete responders (CR) with small cell lung cancer
5. Small-cell carcinoma of lung: reinduction therapy after late relapse
6. Adriamycin resistance in a human small cell lung carcinoma cell line
7. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer